Joel Schlessinger M.D.

The Food and Drug Administration recently approved COSENTYX® (secukinumab) for the treatment of moderate to severe plaque psoriasis. Joel Schlessinger MD and his staff at the Advanced Skin Research Center participated in a successful clinical study with this drug. Their participation was vital in the approval of COSENTYX®.

The study conducted by Joel Schlessinger MD showed COSENTYX® is an innovative treatment option for adults battling plaque psoriasis.

COSENTYX® is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A, which is proven to play an important role in the development of plaque psoriasis. This drug works by inhibiting the body’s immune response, preventing the formation of the red, itchy patches of skin associated with psoriasis. Phase III data showed COSENTYX® resulted in clear or almost clear skin in the majority of patients with moderate to severe plaque psoriasis. COSENTYX® is ideal for adult patients who are candidates for systemic therapy or phototherapy.

Joel Schlessinger MD and his staff at the Advanced Skin Research Center have made several advancements in treatment options for psoriasis patients.

Under the direction of Joel Schlessinger MD, the Advanced Skin Research Center has been active in the advancement of skin care and skin health since 1993. This established dermatology research center provides quality clinical research data to pharmaceutical companies around the world. Each year, the center investigates new medications and treatments for a wide range of skin conditions, as well as cosmetic procedures. Last year, the Advanced Skin Research Center completed two separate yet successful clinical studies for both Tofacitinib and Brodalumab to treat moderate to severe plaque psoriasis.

Do you have a question for Joel Schlessinger MD? Share with us in the comments.